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JOURNAL OF HEPATOLOGYEffect of treatment with polyunsaturated fatty acids on HCV- or
diet-induced fatty liverTo the Editor:
We read with great interest an article recently published in the
Journal of Hepatology [1]. In this study Miyoshi et al. demon-
strate that hepatic over-expression of the hepatitis C virus
(HCV) core protein is able to induce lipid metabolism dysfunc-
tion and fatty liver accumulation in HepG2 cells. In this context,
HCV core protein might directly or indirectly interfere with the
cellular components of hepatocytes, which ultimately contribute
to the onset of steatosis. The authors discuss that one hypothesis
of the direct steatogenic effect of HCV core protein could be
ascribed to the ability of the viral protein to interfere with mito-
chondrial function resulting in the accumulation of NADH. Inter-
estingly, Vial et al., in another recent article published in this
Journal, demonstrate that the impairment of NADH oxidation
to NAD, with consequent NADH accumulation, is a characteristic
ﬁgure of mitochondrial dysfunction occurring in fatty liver due
to high fat diet (HFD) in rats [2]. Furthermore, Miyoshi et al.
[1] demonstrate that, in HepG2 cells, HCV core protein expres-
sion inﬂuences the nature of fatty acids rather than their quan-
tity. These same effects on fatty acid composition are seen in
hepatocytes from HFD rats [2]. Data from these two studies rep-
resent another relevant demonstration of numerous similarities
between fatty liver by HCV, and non-alcoholic fatty liver disease.
Besides fatty liver, chronic hepatitis C resembles NAFLD in
numerous aspects, such as insulin resistance, and oxidative
stress in the liver. Therefore, HCV infection needs to be viewed
not only as a chronic liver disease but also as a metabolic dis-
ease, opening up a novel way to the molecular understanding
of the pathogenesis of chronic hepatitis C, as a virus-associated
fatty liver [3].
Finally, Miyoshi et al. [1] demonstrate that the treatment with
exogenous polyunsaturated fatty acids (PUFAs) reverts the HCV
core protein-associated changes in fatty acid metabolism. Dietary
PUFAs, which are well established negative regulators of hepatic
lipogenesis, are able to alleviate liver inﬂammation and reduce
fat content in steatotic livers [4]. Recently, we demonstrate that
docosahexaenoic acid (DHA) treatment in children with NAFLD
reduces the levels of plasma triglycerides, and improves insulin
resistance and ultrasonographic features of fatty liver [5]. DHA
might downregulate hepatic triglyceride accumulation byJournal of Hepatology 201decreasing transcriptional activity of sterol regulatory element
binding protein-1 (SREBP-1), and inducing fatty acid catabolism
by activating the peroxisome proliferator-activated receptors
(PPARs) [6]. Since Miyoshi et al. suggest that HCV core protein
may induce hepatic triglyceride accumulation by SREBP-1 activa-
tion and consequent desaturase activation, it is probable that
DHA supplementation may be an efﬁcient therapy also to pre-
vent/treat fatty liver associated with HCV infection.
Finally, since insulin resistance is a common metabolic risk of
NAFLD and chronic hepatitis C, we believe DHA might signiﬁ-
cantly reduce hepatic triglyceride content, ameliorating insulin
sensitivity and other metabolic features that associate NAFLD to
HCV infection. These types of treatments, for their almost com-
plete absence of adverse effects, might be suitable for both adults
and children.
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This is a reply to the Letter to the Editor by Comparcola et al.
We appreciate Comparcola and colleagues for their comments
on our ﬁndings about the pathogenesis of lipid metabolism dis-
turbances in hepatitis C virus (HCV) infection [1]. The pathogen-
esis of hepatic steatosis in hepatitis C has been enthusiastically
investigated [2]. Several pathways have been described as mech-
anisms underlying steatogenesis in hepatitis C: the core protein
of HCV inhibits the secretion of very low density lipoprotein
(VLDL) from the liver by suppressing the function of microsomal
triglyceride transfer protein (MTP) [3], increases the production
of fatty acids by upregulating sterol regulatory element binding
protein (SREBP)-1c gene expression [4], and induces hepatic insu-
lin resistance resulting in the increased uptake of fatty acid into
the liver [5]. The combination of these events would lead to a fre-
quent development of steatosis in hepatitis C.
We thank Comparcola et al. for noting that NADH accumulation
is a characteristic feature of mitochondrial dysfunction in a NAFLD
model [6]. We propose that the accumulation of NADH due to dys-
function in themitochondrial electron transfer system (ETS)maybe
responsible for steatogenesis in HCV infection [1]. Interestingly,
tacrolimus, an immunosuppressive agent, reverses the inﬂuence
of the core protein, including hepatic steatosis and insulin resis-
tance, simultaneously with the restoration of mitochondrial ETS
function, as indicated by reduction of NADH accumulation, in a
mouse model [7]. This pathwaymay be a common one in the path-
ogenesis of NASH and hepatitis C, and could be a target for treat-
ment. Hepatitis C should be recognized as a metabolic disease as
well as a hepatic disease that manifests as insulin resistance and
lipid metabolism disorder, resembling NASH, as previously pro-
posed by our team [8] and Balsano et al. [9].
Of importance, exogenously administered polyunsaturated
fatty acids (PUFAs) improve the accumulation and altered com-
position of lipids caused by HCV [1], as well as those in non-alco-
holic fatty liver disease [10]. However, we would like to withhold
our consent for its application in hepatitis C patients, because
PUFAs did not reduce the NADH accumulation in our model sys-
tem, while pyruvate did [1].
Lastly, it is crucial for hepatologists to identify hepatitis C as a
metabolic disease, not only to guide patients toward improving
their life style, but also to invent ameasure to reverse themetabolic
disorders,which are the essential aggravating factors for hepatitis C.
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The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
1326 Journal of Hepatology 20Clara Balsano
Laboratory of Molecular Virology and Oncology, A. Cesalpino
Foundation, University of Rome, Rome, Italytor ‘Effect of treatment with
CV- or diet-induced fatty liver’
References
[1] Miyoshi H, Moriya K, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, et al.
Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated
fatty acids counteract lipid alterations induced by the core protein. J Hepatol
2011;54:432–438, [Epub ahead of print].
[2] Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut
2010;59:1279–1287.
[3] Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, et al.
Hepatitis C virus core protein inhibits microsomal triglyceride transfer
protein activity and very low density lipoprotein secretion: a model of viral-
related steatosis. FASEB J 2002;16:185–194.
[4] Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, et al. Critical
role of PA28gamma in hepatitis C virus-associated steatogenesis and
hepatocarcinogenesis. Proc Natl Acad Sci USA 2007;104:1661–1666.
[5] Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al.
Hepatitis C virus infection and diabetes: direct involvement of the virus in
the development of insulin resistance. Gastroenterology 2004;126:840–848.
[6] Vial G, Dubouchaud H, Couturier K, Cottet-Rousselle C, Taleux N, Athias A,
et al. Effects of a high-fat diet on energy metabolism and ROS production in
rat liver. J Hepatol 2011;54:348–356.
[7] Moriya K, Miyoshi H, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, et al.
Tacrolimus ameliorates metabolic disturbance and oxidative stress caused
by hepatitis C virus core protein: analysis using mouse model and cultured
cells. Am J Pathol 2009;175:1515–1524.
[8] Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohep-
atitis resembling but distinct from NASH. J Gastroenterol 2005;40:329–336.
[9] Balsano C, Alisi A, Nobili V. Liver ﬁbrosis and therapeutic strategies: the goal
for improving metabolism. Curr Drug Targets 2009;10:505–512.
[10] Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids – a
promising novel therapy for non-alcoholic fatty liver disease. Aliment
Pharmacol Ther 2010;31:679–692.
Kazuhiko Koike⇑
Hideyuki Miyoshi
Department of Gastroenterology, Graduate School of Medicine,
The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655,
Japan
⇑ Tel.: +81 3 5800 8800; fax: +81 3 5800 8799.
E-mail address: kkoike-tky@umin.ac.jp (K. Koike)
Hiroshi Yotsuyanagi
Department of Infectious Diseases, Graduate School of Medicine,
The University of Tokyo, Japan
Kyoji Moriya
Department of Infection Control, Graduate School of Medicine,
The University of Tokyo, Japan
11 vol. 54 j 1320–1327
